Centro Hospitalar do Algarve - Hospital de Portimao
About Centro Hospitalar do Algarve - Hospital de Portimao
- Top Sponsors
- Top Collaborators
- Trials By Phase
- Recruitment Status
- Top Conditions
- Intervention Types
- Top Intervention Names
- Trials By Gender
Lead Sponsor
# Trials
Shire
5
Centro Hospitalar Universitario do Algarve
2
Galapagos NV
2
Hoffmann-La Roche
2
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
1
Janssen Research & Development, LLC
1
Janssen-Cilag Ltd.
1
Universidade do Porto
1
Clinical Trials at Centro Hospitalar do Algarve - Hospital de Portimao
During the past decade, Centro Hospitalar do Algarve - Hospital de Portimao conducted 15 clinical trials. In the 10-year time frame, 15 clinical trials started and 7 clinical trials were completed, i.e. on
average, 46.7% percent of trials that started reached the finish line to date. In the past 5 years, 3 clinical trials started and 7 clinical trials were completed. i.e. 233.3%
of trials that started reached the finish line.
Trials List
Trail ID
Brief Title
Start Date
Completion Date
Status
Enrollment
Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Crohn's Disease
2016-10-31
2022-11-11
Completed
1,374
Filgotinib in Long-Term Extension Study of Adults With Crohn's Disease
2017-03-17
2025-01-01
Enrolling by invitation
1,000
Study of Treat to Target Versus Routine Care Maintenance Strategies in Crohn's Disease Patients Treated With Ustekinumab
2017-04-19
2021-07-20
Completed
500
Efficacy and Safety Study of SHP647 as Induction Therapy in Participants With Moderate to Severe Ulcerative Colitis
2017-12-05
2020-10-06
Terminated
279
A Clinical Trial of Omalizumab in Participants With Chronic Rhinosinusitis With Nasal Polyps
2017-11-15
2019-03-11
Completed
138
A Safety Extension Study of Ontamalimab in Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)
2018-02-27
2023-12-31
Active, not recruiting
557
An Efficacy and Safety Study of Ontamalimab as Maintenance Therapy in Participants With Moderate to Severe Ulcerative Colitis
2018-04-04
2021-07-01
Completed
366
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease
2018-04-13
2030-06-30
Active, not recruiting
1,409
Clinical Trials Sponsors and Collaborators
Out of the total clinical trials conducted in "Centro Hospitalar do Algarve - Hospital de Portimao" #1 sponsor was "Shire" with 5 trials, followed by "Centro Hospitalar Universitario do Algarve" with 2 trials
sponsored, "Galapagos NV" with 2 trials sponsored, "Hoffmann-La Roche" with 2 trials sponsored and "Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company"
with 2 trials sponsored. Other sponsors include -2 different institutions and
companies that sponsored additional 8 trials in total.
In terms of collaborators to trials, out of the total clinical trials conducted in "Centro Hospitalar do Algarve - Hospital de Portimao"
#1 collaborator was "Gilead Sciences" with 2 trials as a collaborator, "Universidade do Algarve" with 2 trials as a collaborator, "Universidade do Porto" with 2 trials as a collaborator, "Center for Health Technology and Services Research" with 1 trials as a collaborator and "Linde Health Care" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were
collaborators in the rest 6 trials.
Clinical Trials Conditions at Centro Hospitalar do Algarve - Hospital de Portimao
According to Clinical.Site data, the most researched conditions in "Centro Hospitalar do Algarve - Hospital de Portimao" are
"Crohn's Disease" (6 trials), "Ulcerative Colitis" (3 trials), "Chronic Rhinosinusitis" (2 trials), "Nasal Polyps" (2 trials) and "Anxiety Depression" (1 trials). Many other conditions were trialed in "Centro Hospitalar do Algarve - Hospital de Portimao" in a lesser frequency.
Clinical Trials Intervention Types at Centro Hospitalar do Algarve - Hospital de Portimao
Most popular intervention types in "Centro Hospitalar do Algarve - Hospital de Portimao" are "Drug" (11 trials), "Other" (6 trials) and "Biological" (1 trials). Other intervention types were less common.
The name of intervention was led by "Placebo" (8 trials), "Ontamalimab" (4 trials), "Filgotinib" (2 trials), "Omalizumab" (2 trials) and "Ustekinumab" (2 trials). Other intervention names were less common.
Clinical Trials Genders at Centro Hospitalar do Algarve - Hospital de Portimao
The vast majority of trials in "Centro Hospitalar do Algarve - Hospital de Portimao" are
15 trials for "All" genders.
Clinical Trials Status at Centro Hospitalar do Algarve - Hospital de Portimao
Currently, there are NaN active trials in "Centro Hospitalar do Algarve - Hospital de Portimao".
undefined are not yet recruiting,
2 are recruiting,
2 are Active, not recruiting,
and 1 are Enrolling by invitation.
In total, there were 7 completed trials in Centro Hospitalar do Algarve - Hospital de Portimao,
undefined suspended trials,
and 3 terminated clinical trials to date.
Out of the total trials that were conducted in Centro Hospitalar do Algarve - Hospital de Portimao, 0 "Phase 1"
clinical trials were conducted, 1 "Phase 2" clinical
trials and 11 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 0 trials, and there were
also 0 trials that are defined as “Not Applicable".